Ilsung Pharm (003120) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Ilsung Pharm stock KRW 18,885, price KRW 20,800, that is 9.2% below the price, quality 51 out of 100. Rating: overvalued. Calculated from audited financials with 18 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 8,858 KRW – 28,300 KRW · fair‑value band 18,503 KRW – 19,447 KRW · the 20,800 KRW price screens above the 18,885 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Ilsung Pharm in your weekly email
Every Wednesday you see whether Ilsung Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea.
Show moreShow less
Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products.
The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
Stock analysis
Ilsung Pharm (003120) currently trades at 20,800 KRW, while our model-based Fair Value estimate is 18,885 KRW, 9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 35,369 KRW per share, and 4 of the 18 models we run sit above the 20,800 KRW price.
Bear case: the Growth Earnings group reads lowest at 2,705 KRW, and 14 of the 18 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 18,503 KRW (bear) to 19,447 KRW (bull), the price of 20,800 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ilsung Pharm reported revenue of 64.3B KRW in FY2025 versus 42.1B KRW in FY2021, a compound +11.2%/yr. Reported net income was 1.2B KRW in FY2025.
Key figures
Market cap 142B KRW (≈ $105M) Micro · P/E ratio 26.8 · P/S ratio 2.17 · EPS (TTM) 773.85 KRW · Dividend yield 5.8% · Net margin 8.5% · Return on equity 1.5% · Return on assets (EBIT) −1.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −9%, 003120 screens cheaper than that median.
Fair Value models
Bear18,503 KRWFair Value 18,885 KRWBull19,447 KRW
Price 20,800 KRW · Downside -9.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.69/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
Start year 2020 (pandemic). Over 10 years: +0.4% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−38.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−44.5%
Dividend (yield on the price)5.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−44.5% vs −22.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−5% → −10%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 20.4%/yr over ~7Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +6.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−9.2% · Above median
Profitability
Return on equity (12 months)1.5% · Below median
Return on assets0.3% · Below median
Net margin (12 months)8.5% · Above median
Operating margin (12 months)−9.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)5.1% · Above median
Dividend yield (12 months)5.8% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ilsung Pharm Fair Value". https://www.fairvalue-calculator.com/stock/003120
Frequently asked questions
Is Ilsung Pharm (003120) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 18,885 KRW versus a price of 20,800 KRW, about 9% lower (overvalued).
What is the fair value of 003120?
Our model-based fair value for Ilsung Pharm is 18,885 KRW (as of Nov 5, 2026), built from audited fundamentals. The current price: 20,800 KRW.
What is the quality score of 003120?
Ilsung Pharm has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ilsung Pharm (003120)?
Our model-based price target is the fair value of 18,885 KRW (as of Nov 5, 2026) from 18 valuation models. Cautious scenario 18,503 KRW, optimistic scenario 19,447 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Ilsung Pharm stock forecast for 2026?
Our models put fair value at 18,885 KRW, about 9% lower versus a price of 20,800 KRW (overvalued). Cautious scenario 18,503 KRW, optimistic scenario 19,447 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Ilsung Pharm (003120)?
Ilsung Pharm reported trailing-twelve-month revenue of about 65.2B KRW (latest available figure, as of Nov 5, 2026).
Does Ilsung Pharm pay a dividend?
Ilsung Pharm currently shows a dividend yield of 5.77% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Ilsung Pharm (003120) and when is the ex-dividend date?
Ilsung Pharm pays a dividend of 1,200 KRW per share a year, a dividend yield of 5.8%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since 2000. The payout ratio is 155% of earnings. Free cash flow covers the dividend 0.20 times. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What growth is priced into Ilsung Pharm (003120)?
For today's price to be fair in a discounted-cash-flow model, Ilsung Pharm would have to grow free cash flow by +8.3 % per year for five years (discount rate 13.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.6 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 003120 use?
Our models discount Ilsung Pharm at 13.1 %: a base by market capitalisation (micro), country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ilsung Pharm that is +8.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.1 %) and the same formula as our fair value.
How much growth has Ilsung Pharm (003120) delivered so far?
Over the past 5 years revenue at Ilsung Pharm grew +9.6 % a year. The price currently implies free-cash-flow growth of +8.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ilsung Pharm (003120) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Ilsung Pharm (+8.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ilsung Pharm (003120)?
The free-cash-flow yield on the price is 1.20 %: that much free cash flow Ilsung Pharm produces per unit of market value. When it exceeds the discount rate of our models (13.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ilsung Pharm (003120)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ilsung Pharm it is 18,885 KRW per share (as of Nov 5, 2026), against a price of 20,800 KRW. It is the blended result of 18 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Ilsung Pharm stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 003120 trades above its calculated fair value: price 20,800 KRW, fair value 18,885 KRW, a gap of about −9% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 003120?
No. The price is what the market pays today (20,800 KRW); the fair value is what the company's own numbers justify (18,885 KRW). For Ilsung Pharm the two are 1,915 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Ilsung Pharm worth?
The market values Ilsung Pharm at about 142B KRW (market capitalisation, as of Nov 5, 2026). Per share that is 20,800 KRW; our models calculate a fair value of 18,885 KRW per share.
What do the bullish and bearish scenarios say about 003120?
Our models span a range for Ilsung Pharm: cautious scenario 18,503 KRW, base 18,885 KRW, optimistic 19,447 KRW per share (as of Nov 5, 2026, price 20,800 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 003120?
Ilsung Pharm trades at a price-to-earnings ratio of 26.8 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 18,885 KRW is built from several models across several years. Other multiples: P/B 0.4, P/S 2.2.
How solid is the balance sheet of Ilsung Pharm (003120)?
Balance-sheet figures for Ilsung Pharm (as of Nov 5, 2026): return on equity 1.5%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 003120 from its 52-week high?
Ilsung Pharm trades at 20,800 KRW, about 27% below its 52-week high of 28,300 KRW and 14% above the low of 18,300 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 18,885 KRW is for.
Which stocks are comparable to Ilsung Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ilsung Pharm stock attractive at the current price?
The data as of Nov 5, 2026: price 20,800 KRW, calculated fair value 18,885 KRW (−9%), Quality Score 51/100, from 18 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 003120 calculated?
We run Ilsung Pharm through 18 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 18,885 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ilsung Pharm itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ilsung Pharm (003120)?
The closing price on Nov 6, 2026 was 20,800 KRW. Our model-based fair value is 18,885 KRW, about 9% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ilsung Pharm right now?
The price sits above even our optimistic bull case (19,447 KRW). The favourable scenario is already priced in. The models converge in a tight band (18,503 KRW to 19,447 KRW), unusually little disagreement for a valuation.
Key figures of Ilsung Pharm
How large is the market capitalisation of Ilsung Pharm (003120)?
The market capitalisation of Ilsung Pharm is 142B KRW (≈ $105M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ilsung Pharm (003120)?
The price-to-sales ratio of Ilsung Pharm is 2.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ilsung Pharm (003120)?
Earnings per share at Ilsung Pharm are 773.85 KRW (price ÷ EPS = P/E 26.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ilsung Pharm (003120)?
The dividend yield of Ilsung Pharm is 5.8% (payout 155%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ilsung Pharm (003120)?
The net margin of Ilsung Pharm is 8.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ilsung Pharm (003120)?
The return on equity (ROE) of Ilsung Pharm is 1.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ilsung Pharm (003120)?
On an EBIT basis the return on assets of Ilsung Pharm is −1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ilsung Pharm (003120)?
The operating margin of Ilsung Pharm is −9.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ilsung Pharm (003120)?
Revenue at Ilsung Pharm is growing +5.1% versus a year earlier (3y avg +1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ilsung Pharm (003120)?
Earnings per share at Ilsung Pharm are growing −2.5% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Ilsung Pharm in the live analysis
One click puts Ilsung Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026